Social Starts
VC Fund
San Francisco, United States
Social Starts is a venture capital firm with a data-driven approach to investing in moment-of-inception and Series A financing rounds. The firm prefers to invest in early-stage companies operating in the technology, health tech, internet, and mobile tech sectors.
- Total investments:
- 419
- Last investment:
- Lead investor:
- 2%
- Fund size:
- $8.9M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Social Starts invests in
Stages Social Starts invests in
Countries Social Starts invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 17 contacts → | |||
Round size
- Seed
- $50k–$3.7M
- Series A
- $3.1M–$14M
- Venture - Series Unknown
- $626k–$6.1M
Investment Focus
Industry
- Software 78 (19%)
- Health Care 61 (15%)
- Artificial Intelligence 33 (8%)
- SaaS 28 (7%)
- Mobile 28 (7%)
Stage
- Seed 201 (48%)
- Series A 62 (15%)
- Venture - Series Unknown 24 (6%)
- Pre-Seed 23 (5%)
- Convertible Note 21 (5%)
Country
- United States 257 (61%)
- Canada 7 (2%)
- Germany 6 (1%)
- United Kingdom 6 (1%)
- Japan 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Nicole Staudinger
Director of Marketing
|
Director of Marketing | Total investments: 0 | Find email | |
Toshi Eguchi
Partner
|
Partner | Total investments: 1 | Find email | |
Andrew Nealon
Chief Analyst
|
Chief Analyst | Total investments: 0 | Find email | |
Charles Smith
Venture Partner
|
Venture Partner | Total investments: 10 | Find email | |
Charles Smith
Venture Partner
|
Venture Partner | Total investments: 12 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mae is a maternal health platform that connects expectant mothers with critical resources to drive positive pregnancy outcomes. | Seed / May 07, 2024 | ||
| Ruby Bio is a biosynthesis platform that can manufacture complex molecules that are biodegradable and non-toxic. Ruby Bio uses naturally occurring yeast as a factory to convert low-cost sugar into high-value products. | Seed / Oct 25, 2022 | ||
| Hey Jane is a telehealth startup that connects patients to healthcare providers that offer online medical consultations. The company's innovative Complete Care model utilizes technology for unparalleled layers of support: medical, emotional, and social. Since 2021, Hey Jane has helped nearly 20,000 patients get the care they need. And this isonly the beginning; soon, we will reimagine care for even more common but underserved treatments, with the ultimate goal of becoming the most trusted healthcare company out there—one that pushes the boundaries of access with convenient, inclusive, and patient-driven care. | $6.1M / Venture - Series Unknown / Oct 19, 2022 | ||
| Wayfinder Biosciences is a biotechnology company developing orally available small molecule drugs that modulate the function of the RNAs encoding key disease targets. The company's proprietary platform combines unique screening and computational technologies to rapidly discover potent, selective and biologically active RNA-targeting smallmolecules. Wayfinder's programs are focused on traditionally inaccessible targets in oncology and neurodegenerative disease. Wayfinder Biosciences was established in 2021 and is headquartered in Seattle, WA. | $3.6M / Seed / Oct 17, 2022 | ||
| Fulcrum is a SaaS manufacturing platform designed and built from scratch to bring modern and futuristic concepts to small and mid-sized production shops. The product is a strong vote in favor of decentralized manufacturing, juicing up the system through connectivity and automation. Their long term mission is to create a connected manufacturingsupply chain, reducing tedious data entry, and increasing the speed and efficiency of the entire network supported by the most kickass system available. | $18.8M / Series A / Oct 14, 2022 | ||
| Novel Farms uses microbial fermentation to develop cruelty-free, inexpensive and tunable bioscaffolds for the production of cell-based meat products. Novel Farms mission is to craft the taste and texture of the gourmet meats and transform cell-based meat consumption into a sought-after culinary experience for the next generation of consciouseaters. | $1.1M / Pre-Seed / Aug 10, 2022 | ||
| PhableCare creates an ecosystem of patients, doctors, hospitals, health devices, insurance, and patient care service providers. In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcaresystem. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring. | $24.7M / Series B / Apr 11, 2022 | ||
| Inso Biosciences is an early-stage biotechnology company developing hardware platforms and tools for genomic sample handling. Our patented microfluidic technology, invented and developed at Cornell University, performs high-efficiency processing of cellular material, and we are exploring applications in long-read DNA extraction, multiomic sampleprocessing, and pathogen surveillance.To find out more, please visit our website: www.inso.bio To get in touch with us, please email: contact@inso.bio | $2.3M / Pre-Seed / Feb 11, 2022 | ||
| Epicore Biosystems develops a proprietary wearable microfluidic platform that is ‘skin-like’ and capable of analyzing small droplets of sweat for proteomics, inflammatory markers, hydration, and health biomarkers to enable personalized management of health, performance ,and nutrition. Epicore's wearable sensing technology is based on over twodecades of microfluidics and soft materials research by Prof. John Rogers and Dr. Roozbeh Ghaffari at Northwestern University's Querrey-Simpson Institute for Bioelectronics. | $9.5M / Series A / Feb 09, 2022 | ||
| Hey Jane is a telehealth startup that connects patients to healthcare providers that offer online medical consultations. The company's innovative Complete Care model utilizes technology for unparalleled layers of support: medical, emotional, and social. Since 2021, Hey Jane has helped nearly 20,000 patients get the care they need. And this isonly the beginning; soon, we will reimagine care for even more common but underserved treatments, with the ultimate goal of becoming the most trusted healthcare company out there—one that pushes the boundaries of access with convenient, inclusive, and patient-driven care. | Seed / Jan 01, 2022 | ||
| See all 419 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Social Starts invest in?
Social Starts invests primarily in Software, Health Care and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 419 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Social Starts's check size?
Social Starts typically joins rounds of $50k–$3.7M at Seed, $3.1M–$14M at Series A and $626k–$6.1M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Social Starts participates in.
How do I contact Social Starts?
Public channels for Social Starts include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Social Starts?
The team at Social Starts includes Nicole Staudinger (Director of Marketing), Toshi Eguchi (Partner) and Andrew Nealon (Chief Analyst), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
